


OSCC-IQMH JOINT SCIENTIFIC MEETING 2024



Over, Under, and Through
Harbourfront Centre
Toronto, Ontario, Canada
October 10-11, 2024



A message from Dr. Michael Knauer, OSCC president

OVER, UNDER, AND THROUGH: OVERCOMING CHALLENGES IN THE PURSUIT OF CONTINUOUS IMPROVEMENT

Dear Colleagues and Friends,

On behalf of the Council of the Ontario Society of Clinical Chemists, it is my great privilege to welcome you to the 2024 Annual Scientific Meeting! We have prepared an exceptional scientific program, hosted at the scenic Harborfront Centre in downtown Toronto.

This year's theme, "Over, Under, and Through," emphasizes our collective efforts to overcome challenges in the relentless pursuit of continuous improvement.

I would like to extend my heartfelt thanks to our dedicated and generous sponsors, whose support has made this conference possible. A special acknowledgment goes to our gold sponsors: Beckman Coulter, The Binding Site, DiaSorin, Roche, and Siemens Healthineers.

As I begin my term as OSCC President, I see tremendous opportunities for us to collaborate, drive progress, and advocate for laboratory medicine, especially with the establishment of the Ontario Laboratory Medicine Program. These initiatives are critical for raising public awareness of our profession and supporting the regulated professions initiative.

Finally, I want to express my deepest gratitude to the OSCC Council for their tireless efforts over the past years: Saranya Arnoldo, Dana Bailey, Felix Leung, Curtis Oleschuk, Cristiana Stefan, Ivan Stevic, and Nicole White-Al Habeeb. Your hard work and dedication to the OSCC have been invaluable, and I am excited about what we will achieve together in the years to come.

To our members, thank you for your ongoing support and involvement.

Sincerely,

Dr. Michael Knauer, OSCC President

TABLE OF CONTENTS

P.2	Welcome message
P. 3	Program overview
P. 4—7	Speaker bios and learning
P. 8—9	Sponsorship information
P. 10	About OSCC and IQMH

THANK YOU TO OUR GENEROUS SPONSORS



Beckman Coulter is built on a legacy of innovation which started with our founders, Dr. Arnold Beckman, Wallace and Joseph Coulter who discovered many of the underlying laboratory principles that continue to advance patient care today.

From uncovering the next clinical breakthrough, to rapid and reliable sample analysis, to more rigorous decision making, Beckman Coulter is reimagining laboratory diagnostics by enabling clinicians to deliver the best possible care to their patients with improved efficiency, clinical confidence, adaptive collaboration, and accelerated intelligence.

The increased demand and heightened expectations on diagnostics make high-sensitivity immunoassay testing central to meeting the ever-changing demand of care delivery. Beckman Coulter can revolutionize your core lab's Impact with unprecedented sensitivity.

A highly sensitive clinical analyzer, the DxI 9000 Immunoassay Analyzer is designed to power lab performance across health systems, delivering fast answers with precision and accuracy. The DxI 9000 allows the routine clinical laboratory to enter the realm of new and novel highly sensitive biomarkers for assessing neurological disorders and host response to infection.

Beckman Coulter is a proud continuing sponsor of the 2024 OSCC scientific meeting. Please visit us to learn more of how Beckman Coulter can enhance your laboratory.

GOLD

Day 1 – Thursday, October 10 – Harbourfront Centre, Toronto

8:30 – 9:00

Registration

9:00 – 9:15

Welcome – Michael Knauer

9:15 – 10:45

Symposium 1: IQMH: Investigation of discordant proficiency testing findings

1.5 hour

Attendance Code:

9:15 – 9:45

P1

A. Kumaritakis

From identification to investigation: improving the DFI form

9:45 – 10:45

P2

P. Kavsak

Discordant finding investigations: case studies

10:45 – 11:15

Break, Refreshments, and Vendor Exhibits

11:15 – 1:15

Symposium 2: IQMH: Point of Care

2 hour

Attendance Code:

11:15 – 11:45

P3

J. Shaw

Point of Care Testing utilization in the community

11:45 – 12:15

P4

M. Tadros

Point of Care Testing Biosafety Concerns

12:15 – 12:45

P5

J. Roberts

Quality Standards in POCT

12:45 – 1:15

P6

Roundtable discussion

1:15 – 2:30

Lunch and Vendor Exhibits

2:30 – 4:00

Symposium 3: The laboratory landscape in Ontario

1.5 hour

Attendance Code:

2:30 – 3:00

P7

P. St. Louis

How can looking back help us move forward

3:00 – 3:45

P8

A. Sokoro

Resource Stewardship in Laboratory Medicine: The Manitoba Experience

3:45 – 4:00

P9

M. Asare-Werehene
(trainee)

From vein to vial: validation of plasma free hemoglobin (PFH) testing

4:00 – 6:30

Vendor Exhibits and Refreshments/Wine and Cheese

7:00 –

Dinner: Stratus restaurant, 79 Wellington St W, Toronto, ON M5K 1B1

Day 2 - Friday, October 11 – Harbourfront Centre, Toronto

7:30 – 8:00

Registration and Breakfast

8:00 – 8:30

Annual General Meeting

8:30 – 10:00

Symposium 4: Test underutilization – Improving access to care

1.5 hour

Attendance Code:

8:30 – 9:30

P10

E. Sims

Travelling lectureship – Type 1 Diabetes

9:30 – 10:00

P11

T. Zigras

HPV screening – improving access to care

10:00 – 1:00

Symposium 5: Toxicology & Forensics

2.5 hour

Attendance Code:

10:00 – 11:00

P12

T. Wilkie

Forensic Mental Health System in Ontario

11:00 – 11:45

Break, and Refreshments, vendor exhibits

11:45 – 12:30

P13

C. Stefan

Forensic Laboratory Act 2018 – Impact on Clinical Laboratories

12:30 – 1:00

P14

Open discussion

Toxicology and Forensics

1:00 – 2:00

Lunch, vendor exhibits

2:00 – 3:00

Symposium 6: OSCC trainee presentations

45 min

Attendance Code:

2:00 – 2:15

P15

M.K. Bohn

Evaluation of pre-analytical factors impacting urinalysis and urine chemistry results

2:15 – 2:30

P16

W. Demian

Stability assessment of 16 urinary analytes in 24-hour urine stored at 4°C

2:30 – 2:45

P17

R. Alshamali

The Platelet as a Novel Bio-Source for the Detection of Lyme Borrelia-Derived Protein

2:45 – 3:45

Symposium 7: OSCC members

1 hour

Attendance Code:

2:45 – 3:15

P18

R. Moore

Hyponatraemia – A challenge

3:15 – 3:45

P19

M. Neuman

Psycho-medicine, Cannabis and Gastro-intestinal system

3:45 – 4:00

Student Award Winner

4:00 – 4:15

Closing Remarks



Razan Alshamali

Lyme-Educated Platelets: As A Novel Bio-source for Borrelia burgdorferi derived protein

This talk will discuss the current diagnostic tools for Lyme disease and their limitations. There is a need for new diagnostic tools which are more sensitive in early detection of this disease and are able to distinguish past from current infections. Here, we explore the platelet as a biosource of Borrelia-derived proteins to be used as a liquid biopsy.

Learning Objectives

- 1) Identify the limitations of the current diagnostic tools used in the diagnosis of Lyme disease.
- 2) Understand the phenomenon of platelet education and how it can be used as a diagnostic tool.

I am a second year PhD student at the University of Guelph in the G. Magnotta Lyme Disease research laboratory. We are a philanthropically funded laboratory, working at the intersection of microbiology and human disease, to tackle clinically-significant challenges related to diagnosis, prognosis, and treatment of Lyme.



Meshach Asare-Werehene

From vein to vial: validation of plasma free hemoglobin testing

This talk will describe the validation and implementation of plasma free hemoglobin (PFH) testing at UHN using a Kahn spectrophotometric method that is most precise and has improved turnaround time. Recommended testing process, error sources and prevention will be discussed.

Learning Objectives

- 1) Appreciate that the Kahn spectrophotometric detection of PFH provides acceptable analytical performance for the detection of plasma free hemoglobin.
- 2) Appreciate that compared with H index, the Kahn spectrophotometric is a more sensitive method for detecting and monitoring circuit-induced hemolysis during extracorporeal membrane oxygenation.
- 3) Understand the prevention of errors associated with the validation and implementation of plasma free hemoglobin testing.

Dr. Meshach Asare-Werehene is a clinical biochemistry fellow at the University of Toronto. Prior to joining the clinical chemistry program, he was a Taggart Parkes fellow at the Ottawa Hospital Research Institute investigating the chemo- and immuno-resistance of gynecological cancers. He obtained his doctoral degree in cellular and molecular medicine from the University of Ottawa investigating the immunological landscape of chemoresistant epithelial ovarian cancer.



Mary Kathryn Bohn

Evaluation of pre-analytical factors impacting urinalysis and urine chemistry results

Careful control and consideration of the pre-analytical process is essential to avoid errors and support accurate results and decision-making. This presentation will outline pre-analytical factors to consider in urinalysis and urine chemistry testing and share findings from a novel study assessing stability, volume, and tube type requirements for 24 urine parameters.

Learning Objectives

- 1) Appreciate the need to consider pre-analytical requirements for urinalysis and urine chemistry testing
- 2) Understand the impact of covariates such as time to analysis, specimen volume to preservative ratio, and container type on the accuracy of urine specimen evaluation
- 3) Highlight challenges associated with implementing clinical laboratory practices supported by evidence

Mary Kathryn Bohn obtained her PhD in 2023 at the University of Toronto. Dr. Bohn has published over 50 peer-reviewed manuscripts and presented her work nationally and internationally. Her research has led to recognition from the Canadian Society for Clinical Chemists (CSCC), Canadian Institutes for Health Research (CIHR), and SickKids Research Institute. She is the 2024 recipient of the ADLM George Grannis Award for Excellence in Research and Scientific Publication.



Wael Demian

Stability assessment of 16 urinary analytes in 24-hour urine stored at 4 °C

This lecture will focus on investigating the stability of 16 urine analytes under routine laboratory conditions. There is minimal information on the stability of urinary analytes. Most stability studies have examined stability over a long-term (months to years) using frozen samples (-70 to -20°C). This study is important for add-ons to 24-h urine collections which are more difficult specimens to collect.

Learning Objectives

- 1) Assess the stability of 16 urinary analytes in 24-hour urine stored for 30 days at 4°C.
- 2) Appreciate the limitations or factors that might affect the stability of some urinary analytes.

Wael Demian obtained a MSc in biochemistry at Memorial University, Newfoundland and his PhD in the biochemistry at the University of Toronto, followed by postdoctoral studies at the McMaster Immunology Research Centre (MIRC) where he established several projects linked to biochemistry in virology/immunology lab.



Peter Kavsak

IQMH session on investigating discordant proficiency testing failures

This lecture will discuss important aspects related to discordant results from proficiency testing. The session co-hosted with IQMH will highlight important points for individuals to consider when undertaking a discordant finding investigation (DFI). DFI examples/cases/scenarios will be discussed with the goal for the audience to be able to identify important variables for a successful investigation.

Learning Objectives

- 1) Understand key components for a comprehensive discordant finding investigations (DFIs)
- 2) Appreciate that there different root causes for DFIs

Dr. Peter Kavsak is a prominent researcher and clinical chemist at McMaster University in Hamilton, Ontario. He holds a PhD, postdoctoral diploma in clinical chemistry and specializes in the application of biomarkers for the diagnosis and management of cardiovascular diseases. Dr. Kavsak's research focuses on enhancing the accuracy and effectiveness of laboratory tests, with significant contributions to understanding how biomarkers can improve patient outcomes and guide clinical decision-making. At McMaster University, Dr. Kavsak is also a dedicated educator, involved in teaching and mentoring students and professionals in the field of laboratory medicine. His work is widely published and has influenced clinical practices and guidelines. Through his innovative research and commitment to education, Dr. Kavsak continues to advance the field of clinical chemistry, striving to improve diagnostic precision and patient care.

From identification to investigation: improving the DFI form

This presentation will provide an overview of IQMH's proficiency testing survey analysis and assessment process, focusing on the identification of discordant findings. It will cover feedback on the current discordant findings investigation form and introduce an updated version. The rationale for these updates, including participant feedback and alignment with ISO 15189 standards, will be discussed.

Learning Objectives

- 1) Understand IQMH's approach to survey analysis and identifying discordant findings.
- 2) Appreciate the rationale behind the updates to the discordant findings investigation form.
- 3) Recognize the key elements of the updated discordant findings form.

Alex Kumaritis is a consultant technologist with the Institute for Quality Management in Healthcare (IQMH), supporting the endocrinology, immunology, point of care, and drug proficiency testing programs. He has worked as a medical laboratory technologist at both the bench and senior level, contributing to instrument validation and implementation projects, as well as quality improvement initiatives.



Alex Kumaritis

Hyponatraemia—A challenge

Hyponatraemia is seen in 30% of hospital admission in the USA. This is usually from a chronic illness or drug use. Acute hyponatraemia is seen in ill advised distance runners and during and after major surgeries. The causes, symptoms and consequences of acute and chronic hyponatraemia will be presented.

Learning Objectives

- 1) Know the plasma sodium levels where the clinician should see symptoms of hyponatraemia.
- 2) Be aware of pseudo hyponatraemia - a misleading error caused by some laboratory methods.
- 3) Know the most likely causes of hyponatraemia.

Robert Moore served Sunnybrook Hospital as clinical chemist for 33 years. He has been involved in the education of health care students and graduates since 1963. As an athlete Robert Moore represented Canada at the marathon, on track and cross-country races. He has competed in 1920 events. He has helped to organize and advise more than three hundred races hence his interest in acute hyponatraemia caused by over hydration.



Robert Moore

Psycho-medicine, Cannabis and Gastro-intestinal system

The effectiveness of cannabidiol (CBD) as pharmacotherapy for several chronic pain conditions such as multiple sclerosis, neuropathic pain, and cancer-related pain is well recognized. There is a paucity of reporting on the therapeutic effectiveness of CBD on Inflammatory Bowel Disease (IBD).

Learning Objectives

- 1) Help guide the development of a controlled trial study to determine the benefit and adverse outcomes associated with CBD for IBD.
- 2) Establish the role of CBD in inflammation induced by IBD personalized laboratory biomarkers in IBD that respond to CBD therapy
- 3) Identify possible CBD-interactions with other medications.

Dr. Neuman is an Affiliated Professor of Pharmacology and Toxicology and Associated Global Health at the University of Toronto. She is the founder and CEO of In Vitro Drug Safety and Biotechnology. She wrote 89 research articles and 98 review articles and case reports. In 2021, she received the Research on Alcoholism Lifetime Recognition Award at the ESBR meeting in Timisoara, Romania, and the CSCC Award for Research Excellence.



Manuela Neuman

Quality Standards in POCT

This presentation will cover the current quality/regulatory standards for point-of-care testing (POCT) in Ontario as they apply to laboratory-supported POCT and community based POCT. It will also describe proposed changes to the current accreditation programs and requirements in relation to POCT.

Learning Objectives

- 1) Understand current regulations that impact POCT in Ontario
- 2) Understand proposed changes to accreditation requirements in relation to laboratory-supported POCT in Ontario
- 3) Understand development plans for an accreditation program for community-based POCT

Jennifer has led accreditation assessments for medical laboratories throughout Canada and in several different countries including Senegal and Hong Kong. She also served as project manager for several versions of the accreditation requirements and was responsible for assessor training curriculum and delivery. In 2022, Jennifer accepted the role of Senior Program Manager, and now oversees operations for the ISO 15189 Plus programs at Accreditation Canada Diagnostics.



Jennifer Roberts

Point of Care Testing utilization in the community

This talk will provide a high-level overview of point of care testing (POCT) performed in the community, outside the hospital setting. Current challenges with POCT in the community will be discussed. The new Ontario Laboratory Medicine Program POCT expert panel mandate will also be introduced and discussed.

Learning Objectives

- 1) Compare and contrast POCT performed in hospitals and POCT performed in the community, from regulatory and accreditation perspectives.
- 2) List POCT performed in the community

Julie Shaw is head of the Division of Biochemistry and Point of Care Testing for the Eastern Ontario Regional Laboratories Association and The Ottawa Hospital. She is an Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Ottawa. Julie chairs the point of care testing special interest group of the Canadian Society of Clinical Chemists and is a corresponding member of the International Federation of Clinical Chemistry point of care testing working group. Julie is also the Clinical Lead for the POCT Expert panel of the Ontario Laboratory Medicine Program (OLMP). Julie's research interest is quality assurance for point of care testing



Julie Shaw



Emily Sims

Stages of Type 1 Diabetes, Disease Modifying Therapies in Type 1 Diabetes

Type 1 diabetes is an autoimmune disease yielding destruction of pancreatic beta cells and leading to insulin deficiency. Treatment over the past 100 years has consisted of insulin replacement once affected patients have passed a critical threshold of beta cell loss. However, screening for autoantibodies to pancreatic islets can diagnose T1D in the early presymptomatic stages. Furthermore, novel disease modifying therapies may allow for the delay of insulin requirements in these presymptomatic individuals.

Learning Objectives

- 1) Understand that type 1 diabetes can be identified in a presymptomatic phase.
- 2) Understand that presymptomatic type 1 diabetes typically progresses through a series of stages.
- 3) Understand that disease modifying therapies allow for intervention in the natural history of type 1 diabetes.

Emily K. Sims MD, MS, Associate Professor of Pediatrics at Indiana University School of Medicine, Assistant Director of the Wells Center for Pediatric Research, Associate Director of the IU Medical Scientist Training Program, is an NIH-funded physician scientist specializing in pediatric endocrinology with a research focus on identification of mechanisms and biomarkers of intrinsic beta cell dysfunction contributing to development of type 1 diabetes (T1D); clinical measurements of beta cell function that can be used to understand T1D heterogeneity and responses to disease-modifying therapies; and application of therapeutics aimed at improving beta cell health in T1D.



Abdulrazaq Sokoro

Resource Stewardship in Laboratory Medicine: The Manitoba Experience

This presentation will provide overview of the various resource stewardship initiatives in Laboratory Medicine in Manitoba. It will cover the strategies used and the successes to date.

Learning Objectives

- 1) Appreciate that the Kahn spectrophotometric detection of PFH provides acceptable analytical performance for the detection of plasma free hemoglobin.
- 2) Appreciate that compared with H index, the Kahn spectrophotometric is a more sensitive method for detecting and monitoring circuit-induced hemolysis during extracorporeal membrane oxygenation.
- 3) Understand the prevention of errors associated with the validation and implementation of plasma free hemoglobin testing.

Abdulrazaq (Abdi) Sokoro is the Chief Operating Officer (COO) of Provincial Diagnostic Operations at Shared Health in Manitoba, Canada. Prior to his appointment as COO, Dr. Sokoro served as the Program Director of the Clinical Biochemistry Post-Doctoral Training program at the Max Rady College of Medicine, University of Manitoba (2012-2022), as well as the Lead Clinical Scientist and Executive Director of Provincial Laboratory Operations at Shared Health.



Patrick St. Louis

How can looking back help us move forward

This presentation will review some past advances in the total testing process and discuss how the approaches and rationale behind these may encourage future improvements

Learning Objectives

- 1) Identify some of the factors that contributed to improvements in the total testing process
- 2) Identify areas for further improvements
- 3) Identify, based at least partially on historical considerations, possible approaches to these improvements

Patrick St. Louis has held positions as Clinical Chemist at the Hospital For Sick Children, Toronto and Ste Justine Hospital; Montreal with related University Academic appointments. Other positions include Laboratory Director, LabCorp Clinical Trials, Biochemist and Discipline Head, LifeLabs. Has published in multiple peer-reviewed journals and held positions in National Professional Societies.



Cristiana Stefan

The Forensic Laboratory Act (2018): Critical Appraisal of the Impact on Ontario Clinical Laboratories

The Forensic Laboratory Act (FLA) and its regulations passed in 2018 had an in-force date of January 1, 2024. This presentation aims at critically appraising the impact of the Act on Ontario clinical laboratories based on the assessment performed at the Centre for Addiction and Mental Health (CAMH). The gaps identified and the decisions made will be discussed.

Learning Objectives

- 1) Identify the category of tests to which the Forensic Laboratory Act 2018 and its regulations (the Act) applies and discuss how they relate to tests performed in clinical settings
- 2) Compare and contrast the accreditation requirements prescribed by the Act for the forensic and clinical laboratories and critically discuss how the gaps identified can impact decision making by clinical laboratories
- 3) Appraise the information prescribed by the Act to be included in the laboratory report and critically discuss how the gaps identified can impact decision making by clinical laboratories

Dr. Cristiana Stefan is the Director of the Clinical Laboratory and Diagnostic Services at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada where she practices as Clinical Biochemist/Toxicologist. Dr. Stefan is Scientific Co-Director of the Toronto's Drug Checking Services, is an active member of several professional associations, and participates in the education of clinical and medical fellows.

Point-of-Care Testing Biosafety Decisions

This presentation will review the results of a survey conducted by the Institute of Quality Management in Healthcare and discuss how POCT biosafety decisions were made among participating facilities.

Learning Objectives

- 1) Appreciate the variability among survey participants in how POCT biosafety decisions were made.
- 2) Appreciate the necessity for precise biosafety directives governing POCT practices especially with an anticipated increase in POCT utility.
- 3) Understand the need for enhanced involvement of biosafety experts, encompassing biosafety officers and microbiologists in the formulation of POCT biosafety guidelines.

Manal Tadros, a medical microbiologist at The Hospital for Sick Children, Toronto, has previously worked at Fraser Health Authority in BC, a site director of Infection Control in Burnaby Hospital, and a microbiologist at St. Michael's Hospital, Toronto. Her research focuses on improving rapid and accurate fungal diagnostics as well as early identification of antibiotic resistant organisms. Manal serves as a member of the Advisory Committee for Human Pathogens and Toxins for The Public Health Agency of Canada (PHAC).



Manal Tadros

The Forensic Mental Health System in Ontario: An overview

The forensic mental health system provides care and supervision to persons detained under section 672 of the Criminal Code of Canada after having been found unfit to stand trial or not criminally responsible (NCR) due to mental disorder. This presentation provides information about the Ontario forensic mental health system, and the clinical services provided at the largest provincial forensic program at the Centre for Addiction and Mental Health (CAMH).

Learning Objectives

- 1) Develop an understanding of the forensic mental health system in Ontario
- 2) Consider the factors relevant to risk management, that balance public safety and needs of the individual
- 3) Identify the role of laboratory services in monitoring compliance with Disposition conditions related to risk

Dr. Treena Wilkie is an Associate Professor in the Department of Psychiatry at the University of Toronto, and the Associate Chief Medical Officer at the Centre for Addiction and Mental Health (CAMH). She has been qualified as a specialist in forensic psychiatry by the Royal College of Physicians and Surgeons of Canada, and is the Chief of the Forensic Service, in the Complex Care and Recovery Program at CAMH. Dr. Wilkie is a clinician and educator of psychiatry residents. Her clinical and scholarly interests include the alignment of risk assessment and management principles with recovery based care, and physician wellness and professionalism initiatives.



Treena Wilkie

HPV Screening— Improving Access to Care

This presentation will explore how Primary HPV testing can significantly improve access to cervical cancer screening. We will discuss the benefits of Primary HPV testing over traditional Pap smears, including its higher sensitivity and potential for earlier detection. The talk will also address existing barriers to care and examine how HPV testing can help reduce healthcare disparities by providing a more efficient and cost-effective screening option. Finally, the presentation will explore future directions to further expand access to cervical screening tests.

Learning Objectives

- 1) Discuss the clinical advantages of Primary HPV testing over traditional cytology (Pap smear) in terms of sensitivity, early detection
- 2) Review how Primary HPV testing can improve access to care by offering more efficient and cost-effective screening options.
- 3) Explore practical approaches for integrating Primary HPV testing into screening programs
- 4) Explore Future Directions in HPV Screening and Care Accessibility

Dr. Zigras is a Gynecologic Oncologist at Trillium Health Partners, Credit Valley Hospital. She completed her OB/GYN training at Yale New Haven Health, Bridgeport Hospital, Connecticut, USA. Thereafter, she completed a MSc in Clinical Epidemiology through IHPME at University of Toronto and completed her fellowship in Gynecologic Oncology at the University of Toronto. She is an Assistant Professor in the Department of Obstetrics and Gynaecology, University of Toronto, and is she is the Regional Lead for Cervical Screening and Colposcopy in Mississauga Halton Central West Region. She has an interest in cancer prevention, HPV infections and cancers of the lower genital tract.



Tiffany Zigras

THANK YOU TO OUR GENEROUS SPONSORS

Binding Site, Part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation. Binding Site provides diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders.

Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers, and clinicians for over 30 years.

Our scientific leadership has been continuous since our company was established with first to market assays such as IgG subclasses, Freelite® and an important update recently as announced at ECTRIMS 2024 that Kappa Free Light Chains will be incorporated as a diagnostic test for diagnosis of MS and can be considered interchangeable with OCB. Additionally, this year we expect Health Canada approval for The EXENT® System is an automated solution that enables M-protein identification and measurement in serum with enhanced sensitivity beyond conventional methods. A true breakthrough in monoclonal gammopathy assessment!

We are committed to working in collaboration with our partners and customers to lead the way in specialized medical diagnostics, ensuring we continue to make a difference together.





THANK YOU TO OUR GENEROUS SPONSORS

Diasorin

Diasorin a global leader in the laboratory diagnostics market, specializing in immune and molecular diagnostics segments. For over 50 years, our organization has been developing, manufacturing, and commercializing diagnostic tests; we support clinical laboratory needs and activities, providing solutions that are reliable, innovative, fully automated, and standardized. We continually invest in Research and Development, using our own distinctive expertise in the field to deliver a high level of innovation. Diasorin is a leader in automated stool testing for calprotectin, elastase, and *H. pylori*. We also recently launched the novel test that discriminates between bacterial and viral infections, MeMed BV. These assays are available on the LIAISON XL and LIAISON XS systems.



Diagnos^tics

At Roche Canada, patients and science are at the heart of everything we do. With our combined strength in diagnostics and pharmaceuticals, we're driving personalized healthcare forward and adding our expertise in new areas, like artificial intelligence, real world data collection and analysis and collaborating with different sectors and industries. At Roche Diagnostics, we develop diagnostic tests, instruments and digital solutions with the power to transform healthcare for Canadians. Partnering is critical to driving innovation in Canada. We actively partner with stakeholders across our healthcare systems in order to create solutions that will deliver meaningful benefits - for patients and for sustainable healthcare systems. From all of us at Roche, we thank you, laboratory professionals, for your hard work and dedication to the patients you serve! We invite you to visit our Educational Resources Hubs to access insightful content from the laboratory industry @ lableaders.roche.com and some leadership material for effective decisions @ healthcaretransformers.com.

GOLD

SIEMENS
Healthineers

Siemens Healthineers

We pioneer breakthroughs in healthcare.

For everyone. Everywhere. Sustainably.

Every single healthcare professional feels the pressure to do more.

Handle more patients, run more samples, train more staff, run more reports, make more crucial decisions.

By automating more routine work and designing systems around the practical needs of the laboratory, we help lab staff look up from their screens and spend more time interacting with their colleagues to solve problems and build relationships—closing the distance between people and care. Our human-centered engineering frees people from labor-intensive tasks, allowing them to spend less time on manual work and more time on human work.

At Siemens Healthineers, our goal is simple: less.


Less manual work, less frustration, less administrative burden, less resource demands. And when your staff has less of what they don't need, they're free to do more of the tasks that truly bolster an organization: connecting patients with the care they need.

THANK YOU TO OUR GENEROUS SPONSORS

SILVER



BRONZE





Institute for Quality
Management in Healthcare

OUR MISSION

OSCC—Our mission is to provide Clinical Chemists with provincial representation and aid in informing public policy on laboratory medicine in Ontario. We aim to support and improve the health of all Ontarians by promoting the development and implementation of medical testing to diagnose, treat, and prevent disease. We strive to provide education and resources for Clinical Chemists and other laboratory professionals in Ontario. Our vision is to empower our members to be leaders, advocates, and educators for Ontario medical diagnostic laboratories and to provide exemplary patient-focused laboratory medicine.

WHO WE ARE

IQMH—The entire healthcare system rests on the shoulder of diagnostic testing. When the diagnostic testing system is compromised, it has a negative impact on the whole healthcare system — destroying people's confidence in the system.

IQMH's vision is to be the Standard for Confidence, within the international medical diagnostic testing community.

Our mission is to elevate the integrity of the medical diagnostic testing system by providing rigorous, objective, third-party evaluation according to international standards.

OSCC-IQMH Joint Scientific Meeting 2024

